KONINKLIJKE PHILIPS (PHG) Company Report

KONINKLIJKE PHILIPS N.V. reported Q3 2025 group sales of EUR 4.3 billion, reflecting a 3% increase in comparable sales.
The company achieved 8% comparable order intake growth and expanded its Adjusted EBITA margin by 50 basis points to 12.3% of sales.
Operating cash flow for the quarter was EUR 327 million, with free cash flow at EUR 172 million.
Philips reiterated its full-year 2025 outlook, now expecting the margin at the upper end of the range.

Nov 4, 2025, 3:55 PM

Royal Philips Reports Q3 2025 Financial Results with Strong Sales Growth in Personal Health and Connected Care

PHG

Earnings

Guidance Update

New Projects/Investments

Royal Philips reported 3% comparable sales growth for the group in Q3 2025, driven by 11% growth in Personal Health and 5% growth in Connected Care, while Diagnosis & Treatment grew by 1%.
The group's adjusted EBITDA margin increased by 50 basis points to 12.3%, and adjusted diluted EPS from continued operations rose 13% year-over-year to EUR 0.36. Free cash flow improved significantly by EUR 150 million year-over-year to EUR 172 million.
The company is on track to achieve EUR 800 million in productivity savings for 2025, having already delivered EUR 566 million year-to-date. Cumulative savings since 2023 reached EUR 2.3 billion, exceeding the initial EUR 2 billion target.
Full-year 2025 guidance was reaffirmed for comparable sales growth in the 1%-3% range, with the adjusted EBITDA margin now expected at the upper end of the 11.3%-11.8% range.
The China market remained subdued due to cautious consumer sentiment and centralized procurement, impacting sales, while the company is investing $150 million in the U.S. to expand production and strengthen supply continuity.

Nov 4, 2025, 9:00 AM

Philips Reports Strong Q3 2025 Results and Reaffirms Full-Year Guidance

PHG

Earnings

Guidance Update

Legal Proceedings

Philips (PHG) reported strong Q3 2025 results, with order intake growing 8% and comparable sales increasing 3% year-on-year.
The company's Adjusted EBITDA margin expanded by 50 basis points to 12.3% in Q3 2025, driven by gross margin delivery and productivity, despite tariff impacts.
Philips reiterated its full-year 2025 comparable sales growth outlook of 1%-3% and expects Adjusted EBITDA margin at the upper end of the 11.3%-11.8% range.
Q3 2025 free cash flow was EUR 172 million, contributing to a full-year expectation of EUR 0.2 billion to EUR 0.4 billion, which accounts for a EUR 1 billion outflow from the Respironics settlement in Q1.
An FDA warning letter was issued last week, which the company is fully committed to remediating, though they do not expect it to have a commercial impact.

Nov 4, 2025, 9:00 AM

Philips Reports Strong Q3 2025 Results and Raises Full-Year Adjusted EBITDA Margin Outlook

PHG

Earnings

Guidance Update

Revenue Acceleration/Inflection

Royal Philips reported strong Q3 2025 results, with order intake growing 8% and comparable sales increasing 3% year-on-year. The adjusted EBITDA margin expanded by 50 basis points to 12.3%, and adjusted diluted EPS from continued operations rose 13% to EUR 0.36.
The company raised its full-year 2025 adjusted EBITDA margin outlook to the upper end of the 11.3%-11.8% range, while reiterating comparable sales growth of 1%-3% and free cash flow between EUR 0.2 billion and EUR 0.4 billion.
All business segments contributed to growth, with Personal Health comparable sales increasing 11%, Connected Care growing 5%, and Diagnosis and Treatment improving 1%.
Philips achieved EUR 222 million in productivity savings in Q3, on track for EUR 800 million in 2025, and is actively mitigating an anticipated EUR 150 million-EUR 200 million net tariff impact for the full year.